ClinicalTrials.gg
CompletedNCT07211789REVIDECUpdated Oct 8, 2025

Real World Evidence Study With Restrictive Diet and Otral Nutritional Supplementation on Pediatric Patients With Active Chron Disease

An observational study in Crohn Disease, sponsored by Outcomes'10. Completed at 15 sites in Spain. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-08.

Sponsored by Outcomes'10 · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
58
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Crohn Disease with a site in Spain — 32 open to participants now, 51 under way, 28 of them phase 3. Crohn Disease · Spain.

Enrollment
27th of 31
58 · median 350
Started
2024
with 13 others
Observational
31 of 181
5 open now
Registered
174th of 181
by date

Among the 181 studies in Crohn Disease with a site in Spain, this one is the 27th largest by enrollment of the 31 observational ones that give a count, is one of 14 that started in 2024, is one of 31 observational ones, and was the 174th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

32 of the 181 studies in Crohn Disease with a site in Spain are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Crohn Disease with a site in Spain, or all of them as a file.
02

Study summary

This prospective study aims to provide real-world evidence of the effectiveness of the NEP + CDED diet in paediatric patients with Crohn's disease under conditions of routine clinical practice.

Read the detailed description

Pediatric Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract that impacts growth and quality of life. Exclusive enteral nutrition (EEN) is the standard dietary treatment to induce remission, although its use is limited by low acceptability and strict dietary restrictions.

The combination of partial enteral nutrition (PEN) with the Crohn's Disease Exclusion Diet (CDED) represents a more tolerable alternative that reduces exposure to harmful dietary components and has shown efficacy in inducing clinical remission in previous studies.

This observational, prospective, multicenter study will evaluate the effectiveness of CDED+PEN in routine clinical practice in pediatric patients (8-18 years) with active Crohn's disease. The primary objective is to assess the proportion of patients achieving clinical remission (wPCDAI ≤ 12.5) and mucosal healing (MINI Index \< 8), steroid-free at weeks 6, 12, and 24, and anti-TNF-free at week 24.

Secondary objectives include assessing health-related quality of life (IMPACT-III), treatment satisfaction and gastrointestinal tolerance, treatment persistence, and estimation of healthcare resource utilization and associated costs. The study is observational, descriptive, and non-interventional with respect to drugs, and will be conducted in pediatric patients initiating CDED+PEN as part of standard clinical care. Treatment prescription will be independent of study participation, and patients who receive the indication may be invited to participate after providing informed consent together with their parents or legal guardians.

Primary outcome measures include the frequency of patients in steroid-free clinical remission at weeks 6, 12, and 24, anti-TNF-free remission at week 24, and the proportion achieving mucosal healing (MINI Index \< 8) at the same time points. Secondary analyses will include quality of life scores (IMPACT-III), distribution of questionnaire responses on satisfaction and tolerance, treatment persistence assessed by survival analysis, and cost estimates based on healthcare resource use.

This study will provide real-world evidence on the effectiveness, acceptability, and sustainability of the dietary approach with CDED+PEN in pediatric Crohn's disease under routine clinical practice conditions.

03

Conditions studied

  • Crohn Disease

Keywords

  • Inflammatory Bowel Disease
  • Pediatric Crohn's Disease
  • Children
  • Pediatrics
  • Observational Study
  • Multicenter Study
  • Prospective Study
  • Quality of Life
  • exclusion diet
  • wPCDAI
  • MINI index
04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 8-18 years with Crohn's disease initiating treatment with exclusive enteral nutrition (EEN) plus the Crohn's Disease Exclusion Diet (CDED) and whose wPCDAI value is equal to or greater than 12.5.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Crohn's disease (diagnosis based on clinical, laboratory, endoscopic, radiological, and histological criteria, according to the revised Porto criteria of the ESPGHAN for the diagnosis of inflammatory bowel disease in children and adolescents);
  • Aged between 8 and 18 years;
  • Who are about to start treatment with NEP + CDED, i.e. CDED-naive patients who may have previously received treatment with NEE;
  • With active Crohn's disease defined by the Weighted Paediatric Crohn's Disease Activity Index (wPCDAI) ≥ 12.5;
  • With data collection available for the following 6 months;
  • Able to follow the study protocol or whose parent/caregiver is able to adhere to the study protocol, according to the investigator's perspective.

Exclusion criteria

Exclusion Criteria:

  • Patients with ulcerative colitis and/or unclassified inflammatory bowel disease.
  • Patients with more than 36 months of disease progression.
  • Penetrating (B3) and/or non-inflammatory stenosing (B2) pattern.
  • Active perianal disease.
  • Presence of extraintestinal manifestations.
  • Patients who, in the investigator's opinion, will require surgical treatment or initiation of or biological drugs (anti-TNF, vedolizumab or ustekinumab) within the next 3 months and for whom nutritional support is indicated exclusively as a bridge. Patients who are undergoing biological treatment but discontinue treatment due to non-response and initiate CDED+NEP are not excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
58 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients aged 8-18 years with Crohn's disease initiating treatment with EEN+CDED
06

What researchers measure

Primary outcomes

  1. Effectiveness of the CDED + NEP

    Measurement of absolute and relative frequencies of patients in steroid-free remission

    Time frame: Weeks 6, 12, 24

  2. Effectiveness of the CDED + NEP

    Measurement of absolute and relative frequencies of patients in anti-TNF-free remission

    Time frame: At week 24

  3. Mucosal healing

    The relative and absolute frequencies of patients who have obtained a score of \<8 on the MINI Index will be calculated; this value implies healing of the mucosa.

    Time frame: Weeks 6, 12, 24

Secondary outcomes

  1. Health-related quality of life

    The scores obtained with the HRQoL questionnaire will be calculated

    Time frame: Weeks 6, 12, 24

  2. Satisfaction and acceptability with nutritional treatment

    Based on the distribution of responses to the questionnaire items

    Time frame: Weeks 6, 12, 24

  3. Gastrointestinal tolerance

    Distribution of responses to questionnaire items

    Time frame: Weeks 6, 12, 24

  4. Persistence with the diet

    Percentage of patients who persist with the diet at

    Time frame: Weeks 6, 12, 24

  5. Healthcare resource use and associated costs

    It will be calculated: * Number of visits to professionals who treat the patient (specialist in gastroenterology and paediatric nutrition, primary care, nursing, educational psychologist, social worker, dietitian/nutritionist) * Number of visits to the emergency room per month, * Number of days hospitalised per month, * Number of complementary tests per month, * Number of days of sick leave taken by the caregiver per month, * Number of school days missed per month. For each patient, the monthly cost associated with the use of resources will be estimated by multiplying the frequency of use per month of each resource by its unit cost. Unit costs will be extracted from eSalud.

    Time frame: Weeks 6, 12, 24

07

Study locations

15 sites
  • Complejo Hospitalario Universitario de Albacete
    Albacete, Spain
  • Hospital Torrecárdenas
    Almería, Spain
  • Hospital Sant Joan de Déu
    Barcelona, Spain
  • Hospital Univeristari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario Virgen de la Arrixaca
    El Palmar, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, Spain
  • Hospital Universitario Materno-Infantil de Canarias de Las Palmas
    Las Palmas de Gran Canaria, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Niño Jesús
    Madrid, Spain
  • Hospital Universitario Materno Infantil
    Málaga, Spain
  • Hospital Universitario Central
    Oviedo, Spain
  • Hospital Universitario de Nuestra Señora de la Candelaria
    Santa Cruz de Tenerife, Spain
  • Complejo Hospitalario Universitario de Santiago
    Santiago de Compostela, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, Spain
  • Hospital Universitario la Fe
    Valencia, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Aug 2025, 18 months.

Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's 18 months is below that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 8, 2025
StartActual
Feb 1, 2024
Primary completionActual
Aug 15, 2025
CompletionActual
Aug 15, 2025
Last update
Oct 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211789
Lead sponsor
Outcomes'10
Collaborators
Nestlé Health Science Spain
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Feb 1, 2024
Primary completion
Aug 15, 2025
Completion
Aug 15, 2025
Last update
Oct 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion